[6-5]Identification of ganglioside GD3 as a marker for breast cancer stem cells and development of bispecific T-Cell engaging antibodies for cancer therapy

报告题目：Identification of ganglioside GD3 as a marker for breast cancer stem cells and development of bispecific T-Cell engaging antibodies for cancer therapy

报 告 人：丁尧 博士（Fabion Pharmaceutical, Inc.）

报告时间：2014年6月5日（星期四）下午2:00

报告地点：独墅湖校区二期云轩楼2301室

报告摘要

Cancer stem cells (CSCs) are a small subpopulation of cancer cells that have increased resistance to conventional therapies and are capable of establishing metastasis. However, only a few biomarkers of CSCs have been identified. Here, we identified GD3 as a new CSC-specific cell surface marker and potential therapeutic target for breast cancer. There is increasing evidence that T cells are able to control tumor growth and survival in cancer patients, both in early and late stages of the disease. However, tumor-specific T-cell responses are difficult to mount and sustain in cancer patients, and are limited by numerous immune escape mechanisms of tumor cells selected during immunoediting. A novel approach to engage T cells for cancer therapy are antibodies, which are bispecific for a surface target antigen on cancer cells, and for CD3 on T cells. These are capable of connecting any kind of cytotoxic T cell to a cancer cell, independently of T-cell receptor specificity, costimulation, or peptide antigen presentation.

报告人简介

Dr. Yao ding is a senior scientist at Fabion Pharmaceutical, Inc (Seattle). He is currently focusing on the discovery and development of novel, best-in-class anti-cancer immunotherapeutics. His research activities span a wide range of areas from some fresh approaches for antibody discovery and optimization using phage display, antibody and antibody fragment expression, purification and biochemical characterization.

Dr. Ding earned a PhD degree in molecular microbiology from China Agricultural University in 2009. His graduate studies centered on the mechanism of magnetosome formation in magnetotactic bacteria. After that he joined Professor Sen-itiroh Hakomori at University of Washington as a postdoctoral fellow. In Hakomori’s lab Dr. Ding focused on the study of expression profiles of glycosphingolipids in human breast cancer stem cells (CSCs).